KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Asset Writedowns and Impairment (2016 - 2024)

Idexx Laboratories has reported Asset Writedowns and Impairment over the past 15 years, most recently at $250000.0 for Q1 2024.

  • Quarterly results put Asset Writedowns and Impairment at $250000.0 for Q1 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $250000.0 (down 83.15% YoY), and the annual figure for FY2024 was $250000.0, down 83.15%.
  • Asset Writedowns and Impairment for Q1 2024 was $250000.0 at Idexx Laboratories, down from $1.5 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for IDXX hit a ceiling of $2.0 million in Q3 2020 and a floor of $250000.0 in Q1 2024.
  • Median Asset Writedowns and Impairment over the past 4 years was $1.3 million (2021), compared with a mean of $1.1 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: plummeted 47.52% in 2020 and later crashed 34.77% in 2021.
  • Idexx Laboratories' Asset Writedowns and Impairment stood at $508000.0 in 2020, then surged by 155.91% to $1.3 million in 2021, then increased by 14.15% to $1.5 million in 2023, then plummeted by 83.15% to $250000.0 in 2024.
  • The last three reported values for Asset Writedowns and Impairment were $250000.0 (Q1 2024), $1.5 million (Q4 2023), and $1.3 million (Q3 2021) per Business Quant data.